Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report.

Abstract

ABSTRACT:

Lung adenocarcinoma (LUAD) encompasses all lung epithelial cancers except small-cell lung cancer. Although programmed cell death protein 1 (PD-1) inhibitors, such as pembrolizumab, and other Food and Drug Administration-approved immune checkpoint inhibitors, offer new hope for LUAD treatment, LUAD's overall efficacy remains limited. Thus, the combination of immunotherapy with other therapeutic approaches has gained widespread attention. Local therapy is an optimal method for treating many advanced unresectable lung cancers. Herein, we present a case of a patient with multiple metastases from LUAD, who attained complete response for more than 3 years until present through local therapy combined with a PD-1 inhibitor.

• Authors: Na Wu, Xiaoxin Yang, Yan Zhai, Wei Lu
• Journal: Journal of cancer research and therapeutics (J Cancer Res Ther) Vol. 20 Issue 2 Pg. 739-744 (Apr 01 2024) ISSN: 1998-4138 [Electronic] India
• PMID: 38687948 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2024 Copyright: © 2024 Journal of Cancer Research and Therapeutics.

Chemical References

• Immune Checkpoint Inhibitors
• Antibodies, Monoclonal, Humanized
• Programmed Cell Death 1 Receptor
• pembrolizumab
• PDCD1 protein, human

Topics

• Humans
• Adenocarcinoma of Lung (drug therapy, pathology, therapy, immunology)
• Lung Neoplasms (drug therapy, pathology, therapy)
• Immune Checkpoint Inhibitors (therapeutic use)
• Male
• Immunotherapy (methods)
• Combined Modality Therapy
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Programmed Cell Death 1 Receptor (antagonists & inhibitors)
• Middle Aged
• Treatment Outcome